However, intracerebroventricular delivery of CLN6 gene therapy to the neonatal Cln6 mutant mouse has been shown to prevent or drastically reduce all the pathological hallmarks of NCL, as well as improving behaviour and extending survival [38]. The gene discussed is CLN6; the disease is neuronal ceroid lipofuscinosis.